{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-020454","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.394640+00:00","generated_at":"2026-06-02T22:20:13.856315+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Foghorn Therapeutics reports Q1 2024 net loss $25.0M; cash $206.7M, runway into H1 2026","bullets":["Net loss $25.0M vs $30.5M YoY; collaboration revenue $5.1M, flat vs prior year.","Cash $206.7M as of Mar 31, 2024; expected cash runway into first half of 2026.","FHD-286 combo in AML dose escalation ongoing; initial clinical data expected H2 2024.","IND submitted for FHD-909 (first-in-class oral BRM selective inhibitor); Phase 1 in BRG1-mutated NSCLC expected H2 2024.","Appointed Kristian Humer as CFO in April 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-020454","json":"https://secwatch.observer/filing/0001628280-24-020454.json","markdown":"https://secwatch.observer/filing/0001628280-24-020454.md","text":"https://secwatch.observer/filing/0001628280-24-020454.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828024020454/0001628280-24-020454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828024020454/fhtx-20240506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:20:13.856315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"92939d00dbf1681e24c9355e52d2a0a1b2c4ffc3","claim":"Foghorn Therapeutics Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 6, 2024, Foghorn Therapeutics Inc. (the “Company”) issued a press release announcing certain of the Company’s financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828024020454/0001628280-24-020454-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}